|
|
2005年全球最成功的生物制药公司 |
|
最新一期的 Pharmaceutical Executive 根据全球各生物制药企业2005年的财务表现评出了今年的最成功的生物制药企业。美国的Amgen以29.6%的净利润率和近76万美元的人均销售收入再次蝉联年度最佳公司。排名的标准依据13个财务指标对各公司进行分别评分，然后加权求和，得分最高者为该年度最佳公司。
排行表及各公司的主要财务指标：
|
排名 |
公司 |
销售收入（亿美元） |
销售收入增长率 |
R&D投入(亿美元) |
R&D投入占销售收入比例 |
公司价值变化 |
每股收益(美元) |
市盈率 |
毛利润率 |
|
1 |
Amgen |
120 |
13% |
23 |
19.2% |
5.6% |
2.93 |
23.8 |
83.5% |
|
2 |
Genentech |
55 |
47% |
13 |
23.6% |
1.8% |
1.18 |
68.8 |
85.2% |
|
3 |
Forest |
32 |
21% |
2.93 |
9.2% |
6.4% |
1.92 |
22.3 |
77.3% |
|
4 |
AstraZeneca |
239 |
12% |
54 |
22.6% |
15.5% |
2.40 |
21.5 |
77.8% |
|
5 |
GSK |
340 |
8% |
57 |
16.8% |
4% |
2.04 |
23.3 |
77.9% |
|
6 |
J&J |
223 |
1% |
63 |
28.3% |
-15.8% |
3.46 |
16.6 |
72.4% |
|
7 |
Novartis |
249 |
35% |
45 |
18.1% |
13.4% |
2.22 |
25.3 |
69.7% |
|
8 |
Biogen Idec |
16 |
7% |
7.47 |
46.7% |
11.3% |
0.47 |
95.2 |
85.4% |
|
9 |
Wyeth |
153 |
10% |
13 |
8.5% |
4.3% |
2.70 |
16.9 |
71.3% |
|
10 |
Eli Lilly |
146 |
12% |
30 |
20.5% |
-5.2% |
1.81 |
29.0 |
76.5% |
|
11 |
Merck |
220 |
2% |
38 |
17.3% |
-3.8% |
2.11 |
16.0 |
76.6% |
|
12 |
Bristol-Myers Squibb |
152 |
-2% |
27 |
17.8% |
1% |
1.51 |
16.0 |
69.2% |
|
13 |
Abbott |
140 |
2% |
18 |
12.9% |
-15.8% |
2.16 |
19.1 |
52.5% |
|
14 |
Pfizer |
443 |
-4% |
74 |
16.7% |
-13.8% |
1.09 |
14.6 |
83.4% |
|
15 |
Schering-Plough |
75 |
18% |
19 |
25% |
0.2% |
0.29 |
66.7 |
64.9% |
|
16 |
Sanofi-Aventis |
323 |
4% |
48 |
14.9% |
0.9% |
1.40 |
34.4 |
73.4% |
续表：
| 排名 |
公司 |
净利润率 |
销售收入/资产 |
资产收益 |
财务杠杆比例 |
股票收益 |
人均销售收入(美元) |
知识产权所产生的销售收入比例 |
| 1 |
Amgen |
29.6% |
0.42 |
10.6% |
1.43 |
15.1% |
756,098 |
86.6% |
| 2 |
Genentech |
19.3% |
0.54 |
11.5% |
1.63 |
18.7% |
694,737 |
80.7% |
| 3 |
Forest |
23.8% |
0.86 |
14.6% |
1.18 |
17.3% |
623,053 |
90.0% |
| 4 |
AstraZeneca |
16.2% |
0.53 |
16.3% |
1.42 |
23.2% |
368,259 |
75.6% |
| 5 |
GSK |
15.4% |
0.37 |
16.8% |
1.69 |
28.3% |
370,304 |
81.1% |
| 6 |
J&J |
20.6% |
0.87 |
15.0% |
1.53 |
23.0% |
436,851 |
86.3% |
| 7 |
Novartis |
16.0% |
0.52 |
8.2% |
1.69 |
13.8% |
357,441 |
79.7% |
| 8 |
Biogen Idec |
6.6% |
0.29 |
3.4% |
1.21 |
4.2% |
718,563 |
47.2% |
| 9 |
Wyeth |
19.5% |
0.52 |
8.4% |
2.99 |
25.3% |
376,015 |
77.4% |
| 10 |
Eli Lilly |
13.5% |
0.59 |
9.3% |
2.28 |
21.1% |
342,723 |
66.8% |
| 11 |
Merck |
21.0% |
0.49 |
11.7% |
2.50 |
29.2% |
357,724 |
78.7% |
| 12 |
Bristol-Myers Squib |
16.4% |
0.68 |
9.9% |
2.51 |
24.7% |
446,512 |
81.3% |
| 13 |
Abbott |
15.1% |
0.77 |
11.0% |
2.02 |
22.2% |
373,315 |
84.1% |
| 14 |
Pfizer |
15.7% |
0.44 |
8.0% |
1.79 |
14.3% |
483,962 |
77.9% |
| 15 |
Schering-Plough |
5.3% |
0.61 |
4.0% |
2.09 |
8.3% |
291,411 |
负值 |
| 16 |
Sanofi-Aventis |
10.2% |
0.33 |
3.8% |
1.86 |
7.0% |
348,095 |
76.5% |
数据来源： Bill Trombetta. The Company of the Year: Our Fifth Annual Report dives
deep into the Numbers and Come up with the Industry’s True Top Performers.
Pharmaceutical Executive, Sep. 1, 2006 |
| honghfk 发表于 2007/1/8 13:49:00 | 阅读全文 | 回复(0) | 引用通告 | 编辑 | 收藏该日志 |
|
发表评论：
|
|